Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.
about
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesDPP-4 inhibition and islet functionThe crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanismDipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs.Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum.[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.1999 Jonathan E. Rhoads lecture. Isotopic metaprobes, nutrition, and the roads ahead.Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicityKinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.Proglucagon-derived peptides: mechanisms of action and therapeutic potential.Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.A locus on mouse Chromosome 9 (Adip5) affects the relative weight of the gonadal but not retroperitoneal adipose depot.The role of gut hormones in glucose homeostasisEnhanced insulin secretion and improved glucose tolerance in mice lacking CD26.Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.Glucagon-like peptide 1 (GLP-1) and metabolic diseases.Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic modelAn inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivoSelective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.Topiramate and type 2 diabetes: an old wine in a new bottle.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase-4 inhibitor development.Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models.Comparative Study to Predict Dipeptidyl Peptidase IV Inhibitory Activity of β-Amino Amide Scaffold.Effects of dipeptidyl peptidase-4 inhibition in an animal model of experimental asthma: a matter of dose, route, and timeIdentification and characterization of prokaryotic dipeptidyl-peptidase 5 from Porphyromonas gingivalisAccumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats.The physiology of incretin hormones and the basis for DPP-4 inhibitors.Protein tyrosine phosphatases: their role in insulin action and potential as drug targets.
P2860
Q24628948-099B4B4C-E906-4433-AD11-FEE0A8F82923Q27028127-8BF40453-81AC-4C89-8254-96F864112B4FQ27640960-CA317216-B269-4888-B023-7A8C5E63CD0CQ30652020-CB17D366-9A88-4845-9CD7-06A44A04FAA3Q33184111-0CB5570A-FED9-48FF-8BD7-99AC7E07A50DQ33194892-E5171A5A-4D93-4B2D-BA6E-71165E00B48FQ33237060-FF78EC4A-90D2-4DAC-9CA6-B1E35974C6A4Q33696382-733A848E-8011-492F-B41C-F87559623ADEQ33712562-A18E143C-D8F8-4682-A3AA-7989662B7A49Q34100605-A6247FBC-EEB2-4CBA-B571-222A1F35CC71Q34452524-103F4B32-B597-4320-94A2-B5D132841428Q34569365-9995823D-5923-47CB-AB5A-938D39B30A11Q34589793-C75DAB6F-D4CB-4205-A442-EE925432AB7BQ34620636-103AD5C2-9885-4AB9-A12E-AAD51C64451FQ34648201-A102FFA7-83A8-43DD-8238-E46AEE01E34DQ35189265-530E85EC-7B7B-4580-B92F-152451C607A5Q35222170-43343538-C7E4-4CA1-864F-01C17C1A3E0AQ35251016-F1810F79-437C-4A43-A28B-F9BED5F59C6AQ35809679-45DD1A13-BB64-4742-8EF0-632FE447DB90Q35871904-72B52317-3C25-4C52-8606-CC2D8C3844B5Q35962745-39F968AE-442E-4619-82E7-5B454663B86FQ36309183-BAB36A9D-BAFB-4285-9257-DFDB6B851663Q36470223-76A0E64C-EAA9-4390-AC0E-F4A1812F1F25Q36526318-DDB1D064-6A98-4F47-BB10-C41B42B2BE0DQ36580568-C184D135-1BAF-4C48-B6DD-EE2182322DA2Q36580608-DE47370A-4626-4C39-B802-9E8B4FEB38E5Q36693199-00779081-E174-42C7-B619-4E5C3690DBBBQ36764031-13BD0906-F853-410D-9FC3-67E1D22811DDQ37030881-0BFE86E9-00E1-4346-9F59-0D7D86797D7BQ37941683-380B6D9F-C6B6-442D-A4CE-FA6EE45338A5Q38363899-288BC975-6444-4BDB-A0D4-7E5D61543359Q38698431-2DC5780A-14D4-4615-8AB9-1B55E5659D8FQ38751579-86FD2490-C518-4613-8E80-1625CC1742DCQ39275070-4D9F5A4D-87DD-4BCE-B569-DA5708712F27Q41015928-CCBB11B8-2BCB-485E-A079-318E8E3FD22BQ41866098-885EBCE8-09D2-498B-8BCE-9C39C363B05DQ41984188-0DADDBEA-FA7A-4A4C-A16D-EBC56080A438Q42361286-81D85167-C688-4124-A24B-56670D5C9BC8Q53242373-73372EFA-95FA-45F5-8EC6-B6FD0DC7261BQ53852755-2A32934E-2FD3-46DC-99B1-1FBDF87CEE81
P2860
Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.
description
1998 nî lūn-bûn
@nan
1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Improved glucose tolerance in ...... bitor isoleucine thiazolidide.
@ast
Improved glucose tolerance in ...... bitor isoleucine thiazolidide.
@en
type
label
Improved glucose tolerance in ...... bitor isoleucine thiazolidide.
@ast
Improved glucose tolerance in ...... bitor isoleucine thiazolidide.
@en
prefLabel
Improved glucose tolerance in ...... bitor isoleucine thiazolidide.
@ast
Improved glucose tolerance in ...... bitor isoleucine thiazolidide.
@en
P2093
P356
P1433
P1476
Improved glucose tolerance in ...... bitor isoleucine thiazolidide.
@en
P2093
P304
P356
10.2337/DIAB.47.8.1253
P407
P577
1998-08-01T00:00:00Z